See related article, page 37 Unintended pregnancies and repeat abortion are pressing issues around he world. Recent figures suggest that n the United States, over 1 million uninended pregnancies per year end in aborion. For the patient, abortion can be a ource of emotional distress, and the surical procedure is associated with small isks for bleeding and infection. Overall, nintended pregnancies and abortion repesent a major public health issue. Therefore, attention has recently turned to the safety, efficacy, and patient acceptability of long-acting reversible contraceptive (LARC) methods. These methods include injectable, implantable, and intrauterine devices. This month, Journal Club participants discussed a prospective follow-up study from New Zealand that underscores the value of LARC methods in reducing the rate of repeat abortions. In the original 2008 study, which took place over a 10week period, women were offered free long-acting contraception after abortion— either the levonorgestrel intrauterine system (LNG-IUS), depot medroxyprogesterone acetate (DMPA), or the copper multiload Cu375 IUD (Cu-IUD). Implantable devices were not offered. Patients also received intense education and patient counseling about these methods. They were then contacted by phone at 6 weeks and 6 months to assess continuation rates. At the 6-month mark, investigators reached 78% of the women and learned that 81% with a LNG-IUS and 74% with a Cu-IUD had retained them; 71% of DMPA users were continuing use. For the new study, the rate of repeat abortion was ascertained at 24 months by matching National Health Index numbers (a unique identifier for